BAVISANT DIHYDROCHLORIDE ANHYDROUS

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H27N3O2.2ClH
Molecular Weight	402.358
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of BAVISANT DIHYDROCHLORIDE ANHYDROUS

Structure Search

SMILES

Cl.Cl.O=C(N1CCN(CC1)C2CC2)C3=CC=C(CN4CCOCC4)C=C3

InChI

InChIKey=PBVFXCXXVLBYKF-UHFFFAOYSA-N

InChI=1S/C19H27N3O2.2ClH/c23-19(22-9-7-21(8-10-22)18-5-6-18)17-3-1-16(2-4-17)15-20-11-13-24-14-12-20;;/h1-4,18H,5-15H2;2*1H

HIDE SMILES / InChI

Molecular Formula	C19H27N3O2
Molecular Weight	329.4366
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22519922 | https://www.pmlive.com/pharma_news/benevolentai_raises_$115m_to_fund_drug_development_1232653?SQ_DESIGN_NAME=2

Bavisant (also known as JNJ-31001074 or BEN-2001), a highly selective, active antagonist of the human H3 receptor that was invented by Johnson & Johnson for the treatment of attention-deficit hyperactivity disorder (ADHD). However, the result of clinical trials did not display significant clinical effectiveness in the treatment of adults with ADHD. BenevolentAI has started phase II clinical trials where investigated bavisant for ameliorating the excessive daytime sleepiness in patients with Parkinson’s disease, using one of the drug side effects is dose-dependent insomnia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H3 receptor 46 Target ID: CHEMBL264 Sources: https://www.pharmacodia.com/yaodu/html/v1/chemicals/cc5ddbc0894f9b00110f5f4f29f8574a.html \| https://adisinsight.springer.com/drugs/800031762 \| https://www.medchemexpress.com/bavisant.html	Antagonist 2849

PubMed

Title	Date	PubMed
Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.	2011 Jul 14	21634396

Patents

Sample Use Guides

In Vivo Use Guide

Participants were randomly assigned equally to one of six treatment groups: placebo, bavisant 1 mg/day, 3 mg/day or 10 mg/day, atomoxetine hydrochloride 80 mg/day or osmotic-release oral system (OROS) methylphenidate hydrochloride 54 mg/day.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:42:24 GMT 2025` Edited by `admin` on `Mon Mar 31 19:42:24 GMT 2025`
Record UNII	1B5560RN9F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BAVISANT DIHYDROCHLORIDE ANHYDROUS

Common Name

English

Bavisant dihydrochloride [WHO-DD]

Preferred Name

English

METHANONE, (4-CYCLOPROPYL-1-PIPERAZINYL)(4-(4-MORPHOLINYLMETHYL)PHENYL)-, HYDROCHLORIDE (1:2)

Systematic Name

English

(4-CYCLOPROPYLPIPERAZIN-1-YL)(4-(MORPHOLIN-4-YLMETHYL)PHENYL)METHANONE DIHYDROCHLORIDE

Systematic Name

English

Code System Code Type Description

CAS

929622-09-3